Breast Cancer News

Ipsogen launches a new test to determine tumor HER2 status and guide Herceptin® prescription in breast cancer

 

Ipsogen’s HER2 test further strengthens the rapidly expanding MapQuant Dx™ platform, a microarray-based comprehensive solution designed to guide therapy decisions in breast cancer.

Marseille, Nov. 24,  2008 - IPSOGEN SA (Marseille, France and New Haven, CT, USA), a cancer profiler that markets molecular diagnostic assays for leukemia and breast cancer announced today the European launch of MapQuant Dx™ HER2 test. Developped on the MapQuant Dx™ microarray diagnostic platform, MapQuant Dx™ HER2 accurately measures a set of HER2-amplified genes that correlate with HER2 protein expression. This new HER2 test provides reliable, intelligible and decisive information for pathologists, oncologists and patients.

 “MapQuant™ Dx HER2 is the second test to be developped on our MapQuant Dx™ platform, after the Genomic Grade launched by Ipsogen earlier this year. Thanks to our experience in molecular  diagnostics and to multiple research collaborations, we will keep delivering innovative tests at an accelarated pace.“ says Dr. Jean-Marc Le Doussal, Director of the Breast Cancer Program at Ipsogen.

Commenting on its experience with Ipsogen, Pr. François Bertucci, Medical Oncologist at Institut Paoli Calmettes Cancer Center in Marseille adds: “I was very pleased to collaborate with Ipsogen in rapidly and efficiently moving from our research findings to a market-ready diagnostic test. As a translational researcher, I believe that MapQuant Dx™ is a comprehensive “plug & play” solution, making research rapidly available to patients”.

More

---